Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma

Su Jung Shim, Jinsil Seong, KwangHyub Han, Chae Yoon Chon, Chang-Ok Suh, Jong Tae Lee

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Purpose: In order to determine the effect of additional radiotherapy (RT) after an incomplete transcatheter arterial chemoembolization (TACE) in an unresectable hepatocellular carcinoma (HCC), the treatment results of patients receiving TACE plus RT were analyzed and compared with those treated with TACE alone. Materials and methods: One hundred and five patients with an unresectable HCC were treated with TACE from January 1992 to December 2002. In 73 of these patients, the TACE was incomplete. Among them, TACE was repeatedly performed in 35 patients (TACE group), and the remaining 38 patients were also treated with local RT (TACERT group). The patients were either in stage III or IVa, Eastern Cooperative Oncology Group 2 or less, and Child-Pugh class A or B. The average frequency of TACE prior to RT was 2 and the RT was started within 7-10 days after the TACE. Results: The 2-year survival rate was significantly higher in the TACERT than in the TACE group (36.8% vs. 14.3%, P = 0.001). According to the tumor size, the 2-year survival rates in the TACERT and TACE groups were 63% vs. 42% in 5-7 cm (P = 0.22), 50% vs. 0% in 8-10 cm (P = 0.03), and 17% vs. 0% in larger than 10 cm (P = 0.0002) respectively. Conclusion: There was a significantly improved survival rate in the TACERT group of unresectable HCC patients than in the TACE group, particularly in case of tumors ≥ 8 cm in diameter. Therefore, RT in addition to TACE is strongly recommended for patients with an unresectable HCC.

Original languageEnglish
Pages (from-to)1189-1196
Number of pages8
JournalLiver International
Volume25
Issue number6
DOIs
Publication statusPublished - 2005 Dec 1

Fingerprint

Hepatocellular Carcinoma
Radiotherapy
Survival Rate
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

@article{fbab194ed38e414791bf2798c88300fe,
title = "Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma",
abstract = "Purpose: In order to determine the effect of additional radiotherapy (RT) after an incomplete transcatheter arterial chemoembolization (TACE) in an unresectable hepatocellular carcinoma (HCC), the treatment results of patients receiving TACE plus RT were analyzed and compared with those treated with TACE alone. Materials and methods: One hundred and five patients with an unresectable HCC were treated with TACE from January 1992 to December 2002. In 73 of these patients, the TACE was incomplete. Among them, TACE was repeatedly performed in 35 patients (TACE group), and the remaining 38 patients were also treated with local RT (TACERT group). The patients were either in stage III or IVa, Eastern Cooperative Oncology Group 2 or less, and Child-Pugh class A or B. The average frequency of TACE prior to RT was 2 and the RT was started within 7-10 days after the TACE. Results: The 2-year survival rate was significantly higher in the TACERT than in the TACE group (36.8{\%} vs. 14.3{\%}, P = 0.001). According to the tumor size, the 2-year survival rates in the TACERT and TACE groups were 63{\%} vs. 42{\%} in 5-7 cm (P = 0.22), 50{\%} vs. 0{\%} in 8-10 cm (P = 0.03), and 17{\%} vs. 0{\%} in larger than 10 cm (P = 0.0002) respectively. Conclusion: There was a significantly improved survival rate in the TACERT group of unresectable HCC patients than in the TACE group, particularly in case of tumors ≥ 8 cm in diameter. Therefore, RT in addition to TACE is strongly recommended for patients with an unresectable HCC.",
author = "Shim, {Su Jung} and Jinsil Seong and KwangHyub Han and Chon, {Chae Yoon} and Chang-Ok Suh and Lee, {Jong Tae}",
year = "2005",
month = "12",
day = "1",
doi = "10.1111/j.1478-3231.2005.01170.x",
language = "English",
volume = "25",
pages = "1189--1196",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "6",

}

Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. / Shim, Su Jung; Seong, Jinsil; Han, KwangHyub; Chon, Chae Yoon; Suh, Chang-Ok; Lee, Jong Tae.

In: Liver International, Vol. 25, No. 6, 01.12.2005, p. 1189-1196.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma

AU - Shim, Su Jung

AU - Seong, Jinsil

AU - Han, KwangHyub

AU - Chon, Chae Yoon

AU - Suh, Chang-Ok

AU - Lee, Jong Tae

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Purpose: In order to determine the effect of additional radiotherapy (RT) after an incomplete transcatheter arterial chemoembolization (TACE) in an unresectable hepatocellular carcinoma (HCC), the treatment results of patients receiving TACE plus RT were analyzed and compared with those treated with TACE alone. Materials and methods: One hundred and five patients with an unresectable HCC were treated with TACE from January 1992 to December 2002. In 73 of these patients, the TACE was incomplete. Among them, TACE was repeatedly performed in 35 patients (TACE group), and the remaining 38 patients were also treated with local RT (TACERT group). The patients were either in stage III or IVa, Eastern Cooperative Oncology Group 2 or less, and Child-Pugh class A or B. The average frequency of TACE prior to RT was 2 and the RT was started within 7-10 days after the TACE. Results: The 2-year survival rate was significantly higher in the TACERT than in the TACE group (36.8% vs. 14.3%, P = 0.001). According to the tumor size, the 2-year survival rates in the TACERT and TACE groups were 63% vs. 42% in 5-7 cm (P = 0.22), 50% vs. 0% in 8-10 cm (P = 0.03), and 17% vs. 0% in larger than 10 cm (P = 0.0002) respectively. Conclusion: There was a significantly improved survival rate in the TACERT group of unresectable HCC patients than in the TACE group, particularly in case of tumors ≥ 8 cm in diameter. Therefore, RT in addition to TACE is strongly recommended for patients with an unresectable HCC.

AB - Purpose: In order to determine the effect of additional radiotherapy (RT) after an incomplete transcatheter arterial chemoembolization (TACE) in an unresectable hepatocellular carcinoma (HCC), the treatment results of patients receiving TACE plus RT were analyzed and compared with those treated with TACE alone. Materials and methods: One hundred and five patients with an unresectable HCC were treated with TACE from January 1992 to December 2002. In 73 of these patients, the TACE was incomplete. Among them, TACE was repeatedly performed in 35 patients (TACE group), and the remaining 38 patients were also treated with local RT (TACERT group). The patients were either in stage III or IVa, Eastern Cooperative Oncology Group 2 or less, and Child-Pugh class A or B. The average frequency of TACE prior to RT was 2 and the RT was started within 7-10 days after the TACE. Results: The 2-year survival rate was significantly higher in the TACERT than in the TACE group (36.8% vs. 14.3%, P = 0.001). According to the tumor size, the 2-year survival rates in the TACERT and TACE groups were 63% vs. 42% in 5-7 cm (P = 0.22), 50% vs. 0% in 8-10 cm (P = 0.03), and 17% vs. 0% in larger than 10 cm (P = 0.0002) respectively. Conclusion: There was a significantly improved survival rate in the TACERT group of unresectable HCC patients than in the TACE group, particularly in case of tumors ≥ 8 cm in diameter. Therefore, RT in addition to TACE is strongly recommended for patients with an unresectable HCC.

UR - http://www.scopus.com/inward/record.url?scp=28944444790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28944444790&partnerID=8YFLogxK

U2 - 10.1111/j.1478-3231.2005.01170.x

DO - 10.1111/j.1478-3231.2005.01170.x

M3 - Article

C2 - 16343071

AN - SCOPUS:28944444790

VL - 25

SP - 1189

EP - 1196

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 6

ER -